Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2026)
Allogene Therapeutics (ALLO) reported EBITDA Margin of -954.20% for Q2 2026.
Powered by 
Analysis
Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Allogene Therapeutics' EBITDA Margin came in at -3633.79%; for FY2024, it came in at -1179818.18%, down 849779.23 percentage points from FY2023.
- EBITDA Margin has declined for three consecutive years, with a three-year change of -1179669.40 percentage points (FY2021 to FY2024).
- By year, EBITDA Margin came in at -330038.95% in FY2023 (-124115.23 pp), -205923.72% in FY2022 (-205774.94 pp) and -148.78% in FY2021.
- The Q2 2026 figure ranks as the highest quarterly EBITDA Margin since Q4 2021.
- The high point for year-over-year EBITDA Margin in five years was Q2 2022 (a gain of 42995.60 percentage points); the low point was Q4 2022 (a drop of 358957.86 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 39.16% |
| 10 | Allogene Therapeutics | 435.17 Mn | -666.72 Mn | - | -954.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -954.20% |
| Mar 31, 2024 | -299,768.18% |
| Dec 31, 2023 | -388,719.05% |
| Sep 30, 2023 | -270,109.09% |
| Jun 30, 2023 | -349,531.82% |
| Mar 31, 2023 | -318,616.67% |
| Dec 31, 2022 | -358,950.00% |
| Sep 30, 2022 | -291,300.00% |
| Jun 30, 2022 | -113,970.31% |
| Mar 31, 2022 | -195,697.44% |
| Dec 31, 2021 | 7.86% |
| Sep 30, 2021 | -153,755.10% |
| Jun 30, 2021 | -156,965.91% |
| Mar 31, 2021 | -81.58% |
API Access
Allogene Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ALLO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "ALLO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ALLO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();